Harley Smoot
Psychiatry · Germantown, MDNPI 1316918493
Payments from drug & device makers
Across 125 payments — averaging $38.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- Alkermes, Inc.$583
- Teva Pharmaceuticals USA, Inc.$571
- AbbVie$475
- Neurocrine Biosciences, Inc.$329
- plus $685 from 10 others
What the payments were for
- Food & beverage$4,73399%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $1,103 |
| Johnson & Johnson | 23 | $1,016 |
| Alkermes, Inc. | 14 | $583 |
| Teva Pharmaceuticals USA, Inc. | 11 | $571 |
| AbbVie(2 entities) | 15 | $475 |
| Neurocrine Biosciences, Inc. | 11 | $329 |
| Sunovion Pharmaceuticals Inc. | 3 | $133 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| Vanda Pharmaceuticals Inc. | 7 | $118 |
| Indivior Inc. | 6 | $108 |
| E.r. Squibb & Sons, L.L.C. | 3 | $70 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Lundbeck LLC | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,462
- INVEGA SUSTENNA$500
- ABILIFY MAINTENA$483
- ARISTADA INITIO$366
- REXULTI$341
- ABILIFY ASIMTUFII$241
- VRAYLAR$238
- Austedo XR$237
- UZEDY$231
- INGREZZA$127
- Auvelity$124
- SPRAVATO$122
- LATUDA$108
How this compares
$4,761 in reported general payments places this provider in the 90th percentile of 851 psychiatry providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 23 | $217,429 |
| Invega SustennaPaliperidone Palmitate | 56 | $192,486 |
| IngrezzaValbenazine Tosylate | 23 | $175,231 |
| AristadaAripiprazole Lauroxil | 26 | $52,087 |
| VraylarCariprazine Hcl | 12 | $20,116 |
| VivitrolNaltrexone Microspheres | 11 | $18,234 |
| TrintellixVortioxetine Hydrobromide | 11 | $16,533 |
| Lurasidone Hcl | 24 | $13,656 |
| Divalproex Sodium ErDivalproex Sodium | 58 | $3,586 |
| Quetiapine Fumarate | 59 | $3,135 |
| Fluphenazine Decanoate | 24 | $2,531 |
| Paliperidone ErPaliperidone | 13 | $2,507 |
| Carbamazepine ErCarbamazepine | 20 | $2,260 |
| Haloperidol | 41 | $2,179 |
| Trazodone Hcl | 129 | $2,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $1,016 | $409,91479 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $329 | $175,23123 claims |
| Alkermes, Inc.Aristada, Vivitrol | $583 | $70,32137 claims |
| AbbVieVraylar | $475 | $20,11612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $26 | $16,53311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Germantown
- Elia Acevedo DiazGaithersburg$15.8M
- Akira SawaBaltimore$5.1M
- John VaethBaltimore$2.1M
- Paul RosenbergBaltimore$1.9M
- Scott AaronsonBaltimore$1.3M
- Karen AndersonBaltimore$1.1M
- Constantine LyketsosBaltimore$1.1M
- Alan JonasBaltimore$1.1M
- Sarah HertsBaltimore$1M
- Robert LehmanBaltimore$947K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.